ArticlePloS one2011
Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 125 citations in OpenAlex.
- Design Strategies for Developing Chiral Macrocyclic Chelators as a Diagnostic Tool.Accounts of chemical research · 2026Article
- [Npj imaging · 2026Article
- Side by side comparison of NOTA and DOTA for conjugation efficiency, gallium-68 labeling, and in vivo biodistribution of anti-mesothelin sdAb A1-His.EJNMMI radiopharmacy and chemistry · 2025Article
- Advances in immunoPET/SPECT imaging: The role of Fab and F(ab')Acta pharmaceutica Sinica. B · 2025Review
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Is Copper-61 the New Gallium-68? Automation and Preclinical Proof-of-Concept ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Immuno-PET Imaging of CD93 Expression withMolecular pharmaceutics · 2024Article
- Tuning the Properties of Rigidified Acyclic DEDPAInorganic chemistry · 2024Article
- Approaches to Reducing Normal Tissue Radiation from Radiolabeled Antibodies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Noninvasive PET imaging of tumor PD-L1 expression withAmerican journal of nuclear medicine and molecular imaging · 2024Article
- Design, Synthesis, and Biological Evaluation of Small-Molecule-Based Radioligands with Improved Pharmacokinetic Properties for Imaging of Programmed Death Ligand 1.Journal of medicinal chemistry · 2023Article
- Comparison of the Effects of DOTA and NOTA Chelators onDiagnostics (Basel, Switzerland) · 2023Article
- Nanomaterial-based contrast agents.Nature reviews. Methods primers · 2023Article
- Positron Emission Tomography Probes for Imaging Cytotoxic Immune Cells.Pharmaceutics · 2022Review
- The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker.Molecules (Basel, Switzerland) · 2022Review
- Nanotheranostics for Image-Guided Cancer Treatment.Pharmaceutics · 2022Review
- Drug development concerning metallo-β-lactamases in gram-negative bacteria.Frontiers in microbiology · 2022Review
- Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders-An Update.Cancers · 2020Review
- Article
- Multimodal Nanocarrier Probes Reveal Superior Biodistribution Quantification by Isotopic Analysis over Fluorescence.ACS nano · 2020Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Optimizing the in vivo stability of positron emission tomography (PET) tracers is of critical importance to cancer diagnosis. In the case of (64)Cu-labeled monoclonal antibodies (mAb), in vivo behavior and biodistribution is critically dependent on the performance of the bifunctional chelator used to conjugate the mAb to the radiolabel. This study compared the in vivo characteristics of (64)Cu-labeled TRC105 (a chimeric mAb that binds to both human and murine CD105), through two commonly used chelators: 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Flow cytometry analysis confirmed that chelator conjugation of TRC105 did not affect its CD105 binding affinity or specificity. PET imaging and biodistribution studies in 4T1 murine breast tumor-bearing mice revealed that (64)Cu-NOTA-TRC105 exhibited better stability than (64)Cu-DOTA-TRC105 in vivo, which resulted in significantly lower liver uptake without compromising the tumor targeting efficiency. In conclusion, this study confirmed that NOTA is a superior chelator to DOTA for PET imaging with (64)Cu-labeled TRC105.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.